KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Invested Capital (2016 - 2025)

Historic Invested Capital for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $6.1 billion.

  • Biomarin Pharmaceutical's Invested Capital rose 1188.38% to $6.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 billion, marking a year-over-year increase of 1188.38%. This contributed to the annual value of $5.7 billion for FY2024, which is 390.35% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Invested Capital stood at $6.1 billion for Q3 2025, which was up 1188.38% from $6.0 billion recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Invested Capital ranged from a high of $6.1 billion in Q3 2025 and a low of $4.2 billion during Q1 2021
  • In the last 5 years, Biomarin Pharmaceutical's Invested Capital had a median value of $4.8 billion in 2023 and averaged $5.0 billion.
  • Its Invested Capital has fluctuated over the past 5 years, first tumbled by 257.07% in 2021, then skyrocketed by 2087.28% in 2024.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Invested Capital stood at $4.3 billion in 2021, then increased by 7.07% to $4.6 billion in 2022, then grew by 17.89% to $5.4 billion in 2023, then increased by 3.9% to $5.7 billion in 2024, then increased by 7.05% to $6.1 billion in 2025.
  • Its last three reported values are $6.1 billion in Q3 2025, $6.0 billion for Q2 2025, and $5.8 billion during Q1 2025.